Author/Authors :
Hamed, Rasha Hamdy Clinical Oncology and Nuclear Medicine Department - Faculty of Medicine - Mansoura University, Mansoura, Egypt , Sakr, Hanem Clinical Oncology and Nuclear Medicine Department - Faculty of Medicine - Mansoura University, Mansoura, Egypt , Lotfy, Ahmed General Surgery Department - Faculty of Medicine - Mansoura University, Mansoura, Egypt
Abstract :
Background: Anaplastic thyroid carcinoma is an extremely aggressive cancer that
has a very poor outcome. We have analyzed predictive factors for overall survival
and different therapeutic modalities that could help to determine the optimal therapy
for this carcinoma.
Methods: We performed a retrospective analysis of data from 54 cases of
anaplastic thyroid carcinoma to evaluate demographic, pathological, and clinical characteristics,
along with therapeutic modalities that affected survival. The Kaplan-Meier
curve was used to visualize the cumulative probability of survival and comparison
among/between groups was performed with the log-rank test. A multivariate Cox
proportional hazards model was used to examine overall survival.
Results: We observed overall survival percentages of 50% (one-year), 25% (2-
year), and 5.6% (5-year). The 2-year overall survival was 41.7% for stage IVA, 31.5%
for stage IVB, and 7.4% for stage IVC (P= 0.04). The 2-year overall survival rates
were 59.3% for patients with negative margins, 30.1% for those with positive
margins, and 0.0% in the group without thyroidectomy (P=0.005). Surgery plus
postoperative radiotherapy indicated better 2-year overall survival (56%) compared
to surgery alone (34.7%, P<0.005). Multivariate analysis showed that factors
predictive of improved overall survival included tumor size (≤5 cm), duration of
complaint >one month, no reported metastasis at presentation, negative surgical
margins, surgery, radiotherapy, and/or chemotherapy.
Conclusion: Anaplastic thyroid carcinoma is an aggressive cancer with a very
poor prognosis. Multimodality treatment may improve overall survival in these
patients. Duration of symptoms, primary tumor size, distant metastases, surgical
treatment, surgical margin status, radiotherapy, and chemotherapy are independent
factors that affect prognosis.